HALOZYME THERAPEUTICS, INC. Cost of Revenue
HALOZYME THERAPEUTICS, INC. (HALO) reported Cost of Revenue of $79.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $79.17M, a 70.78% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $79.24M, a 63.70% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $78.77M, a 87.30% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $55.24M, a 11.77% increase year-over-year.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for fiscal 2025 was $228.77M, a 43.51% increase from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for fiscal 2024 was $159.42M, a 17.13% decline from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for fiscal 2023 was $192.36M, a 38.09% increase from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. cost of goods and services sold for fiscal 2022 was $139.30M, a 71.11% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $79.17M 10-Q · filed 2026-08-06 | $158.41M 10-Q · filed 2026-08-06 | $237.18M derived: sum of 3 quarters · filed 2026-08-06 | $292.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $79.24M 10-Q · filed 2026-05-11 | $158.01M derived: sum of 2 quarters · filed 2026-05-11 | $213.25M derived: sum of 3 quarters · filed 2026-05-11 | $259.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $78.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $134.01M derived: sum of 2 quarters · filed 2026-02-17 | $180.37M derived: sum of 3 quarters · filed 2026-08-06 | $228.77M 10-K · filed 2026-02-17 |
| 2025-09-30 | $55.24M 10-Q · filed 2025-11-03 | $101.60M derived: sum of 2 quarters · filed 2026-08-06 | $150.00M 10-Q · filed 2025-11-03 | $192.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $46.36M 10-Q · filed 2026-08-06 | $94.76M 10-Q · filed 2026-08-06 | $136.82M derived: sum of 3 quarters · filed 2026-08-06 | $186.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $48.40M 10-Q · filed 2026-05-11 | $90.46M derived: sum of 2 quarters · filed 2026-05-11 | $139.88M derived: sum of 3 quarters · filed 2026-05-11 | $179.49M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $42.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $91.48M derived: sum of 2 quarters · filed 2026-02-17 | $131.09M derived: sum of 3 quarters · filed 2026-02-17 | $159.42M 10-K · filed 2026-02-17 |
| 2024-09-30 | $49.43M 10-Q · filed 2025-11-03 | $89.03M derived: sum of 2 quarters · filed 2025-11-03 | $117.36M 10-Q · filed 2025-11-03 | $169.66M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $39.61M 10-Q · filed 2025-08-05 | $67.94M 10-Q · filed 2025-08-05 | $120.23M derived: sum of 3 quarters · filed 2026-02-17 | $175.06M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $28.33M 10-Q · filed 2025-05-06 | $80.63M derived: sum of 2 quarters · filed 2026-02-17 | $135.45M derived: sum of 3 quarters · filed 2026-02-17 | $185.52M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $52.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $107.12M derived: sum of 2 quarters · filed 2026-02-17 | $157.19M derived: sum of 3 quarters · filed 2026-02-17 | $192.36M 10-K · filed 2026-02-17 |
| 2023-09-30 | $54.82M 10-Q · filed 2024-10-31 | $104.89M derived: sum of 2 quarters · filed 2024-10-31 | $140.06M 10-Q · filed 2024-10-31 | $182.18M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $50.07M 10-Q · filed 2024-08-06 | $85.24M 10-Q · filed 2024-08-06 | $127.36M derived: sum of 3 quarters · filed 2025-02-18 | $174.68M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $35.17M 10-Q · filed 2024-05-07 | $77.29M derived: sum of 2 quarters · filed 2025-02-18 | $124.61M derived: sum of 3 quarters · filed 2025-02-18 | $158.55M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $42.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $89.44M derived: sum of 2 quarters · filed 2025-02-18 | $123.38M derived: sum of 3 quarters · filed 2025-02-18 | $139.30M 10-K · filed 2025-02-18 |
| 2022-09-30 | $47.32M 10-Q · filed 2023-11-06 | $81.26M derived: sum of 2 quarters · filed 2023-11-06 | $97.18M 10-Q · filed 2023-11-06 | $118.77M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $33.94M 10-Q · filed 2023-08-08 | $49.87M 10-Q · filed 2023-08-08 | $71.45M derived: sum of 3 quarters · filed 2024-02-20 | $90.04M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $15.92M 10-Q · filed 2023-05-09 | $37.51M derived: sum of 2 quarters · filed 2024-02-20 | $56.10M derived: sum of 3 quarters · filed 2024-02-20 | $79.12M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $21.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $40.18M derived: sum of 2 quarters · filed 2024-02-20 | $63.19M derived: sum of 3 quarters · filed 2024-02-20 | $81.41M 10-K · filed 2024-02-20 |
| 2021-09-30 | $18.59M 10-Q · filed 2022-11-08 | $41.61M derived: sum of 2 quarters · filed 2022-11-08 | $59.83M 10-Q · filed 2022-11-08 | $86.10M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $23.02M 10-Q · filed 2022-08-09 | $41.24M 10-Q · filed 2022-08-09 | $67.51M derived: sum of 3 quarters · filed 2023-02-21 | $73.08M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $18.22M 10-Q · filed 2022-05-10 | $44.49M derived: sum of 2 quarters · filed 2023-02-21 | $50.06M derived: sum of 3 quarters · filed 2023-02-21 | $55.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $26.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $31.84M derived: sum of 2 quarters · filed 2023-02-21 | $37.58M derived: sum of 3 quarters · filed 2023-02-21 | $43.37M 10-K · filed 2023-02-21 |
| 2020-09-30 | $5.57M 10-Q · filed 2021-11-02 | $11.31M derived: sum of 2 quarters · filed 2021-11-02 | $17.09M 10-Q · filed 2021-11-02 | $33.78M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $5.74M 10-Q · filed 2021-08-09 | $11.53M 10-Q · filed 2021-08-09 | $28.21M derived: sum of 3 quarters · filed 2022-02-22 | $50.55M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $5.79M 10-Q · filed 2021-05-10 | $22.47M derived: sum of 2 quarters · filed 2022-02-22 | $44.81M derived: sum of 3 quarters · filed 2022-02-22 | $46.68M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $16.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $39.02M derived: sum of 2 quarters · filed 2022-02-22 | $40.90M derived: sum of 3 quarters · filed 2022-02-22 | $45.55M 10-K · filed 2022-02-22 |
| 2019-09-30 | $22.33M 10-Q · filed 2020-11-02 | $24.21M derived: sum of 2 quarters · filed 2020-11-02 | $28.86M 10-Q · filed 2020-11-02 | $34.48M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $1.88M 10-Q · filed 2020-08-10 | $6.53M 10-Q · filed 2020-08-10 | $12.15M derived: sum of 3 quarters · filed 2021-02-23 | $12.77M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $4.65M 10-Q · filed 2020-05-11 | $10.27M derived: sum of 2 quarters · filed 2021-02-23 | $10.90M derived: sum of 3 quarters · filed 2021-02-23 | $11.73M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $6.25M derived: sum of 2 quarters · filed 2021-02-23 | $7.08M derived: sum of 3 quarters · filed 2021-02-23 | $10.14M 10-K · filed 2021-02-23 |
| 2018-09-30 | $626.00K 10-Q · filed 2019-11-12 | $1.46M derived: sum of 2 quarters · filed 2019-11-12 | $4.51M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $836.00K 10-Q · filed 2019-08-06 | $3.89M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $3.05M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $31.15M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |